When we broke out the EBV negative GC by MSI status we found that MSI GCs had PD-L1+ tumor and immune cells in 33% (5/15) and 46% (7/15) of cases respectively, which was higher than EBV negative microsatellite stable (MSS) GCs that had no PD-L1 positive tumor cells (0% (0/34), P < 0.001) and PD-L1 positive immune cells in only 35% of cases (12/34, P < 0.001). This evidence concerns the gene CD274 and neoplasm.